

EV1232

F17464 a new antipsychotic with preferential D3 antagonist, 5-HT_{1A} partial agonist properties. Neurochemical studies

C. Cosi*, V. N'Guyen, N. Consul-Denjean, A. Auclair, P. Heusler, J.C. Martel, L. Leriche, P. Sokoloff, S. Gatti-McArthur

Institut de recherche Pierr-Fabre, centre d'évaluation préclinique, unité innovation SNC, Castres, France

* Corresponding author.

F17464 is a new dopamine receptor antagonist that recently demonstrated antipsychotic activity in a proof of concept study in schizophrenic patients under acute exacerbation. The compound has a unique profile with high affinity for hD₃ receptors (K_i=0.17 nM) and lower affinity for hD_{2L} (K_i=12.1 nM) and hD_{2S} (K_i=6.5 nM). F17464 exhibits also high affinity for h5-HT_{1A} receptors (K_i=0.16 nM). F17464 is a hD₃ antagonist (pK_B=9.13), hD_{2S} very weak partial agonist (pK_B=7.87, emax 8% of DA stimulated in ERK assay) and a 5-HT_{1A} partial agonist (pEC₅₀=7.99). F17464 exhibits consistent affinities for rat striatal D₂ (K_i=4.8 nM) and for rat hippocampal 5-HT_{1A} receptors (K_i=1.14 nM). Neurochemical studies show that F17464 ip (1 h post-dose) produces a significant dose-dependent increase in the levels of DOPAC and HVA in the frontal cortex, caudate-putamen and limbic forebrain and an increase in 3-MT levels in the latter two regions with no changes in total DA content. The effect is significant at the doses of 0.63–2.5 mg/kg ip (PK/PD data will be provided). This pattern of DA metabolite changes is similar to that described for several antipsychotic drugs in rodents and it is indicative of a cortical effect of F17464. F17464 has a very low cataleptogenic activity in rats and mice and does not induce serotonergic signs typical of 5-HT_{1A}. F17464 is therefore a novel a D₃ preferential antipsychotic with a unique mechanism of action and receptor affinity profile and a consistent effect in neurochemistry studies in rodents.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2017.01.1562>

EV1233

A novel methodology to evaluate the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology

D. Cox*, M. Gottschalk, H. Wesseling, A. Ernst, J. Cooper, S. Bahn

Cambridge Centre for Neuropsychiatric Research, Institute of Biotechnology, Cambridge, United Kingdom

* Corresponding author.

Rodent models of schizophrenia (SCZ) are indispensable when screening for novel treatments, but quantifying their translational relevance with the underlying human pathophysiology has proved difficult. A novel systems methodology (shown in [Figure 1](#)) was developed integrating and comparing proteomic data of anterior prefrontal cortex tissue from SCZ post-mortem brains and matched controls with data obtained from four established glutamatergic rodent models, with the aim of evaluating which of these models represent SCZ most closely. Liquid chromatography coupled tandem mass spectrometry (LC-MS^E) proteomic profiling was applied comparing healthy and “disease state” in human post-mortem samples and rodent brain tissue samples. Protein-protein interaction networks were constructed from significant abundance changes and enrichment analyses enabled the identification of pathophysiological characteristics of the disorder, which were represented across all four rodent models. Subsequently, these functional domains were used for cross-species comparisons.

Five functional domains such as “development and differentiation” represented across all four rodent models, were identified. It was quantified that the chronic phencyclidine (cPCP) model represented SCZ brain changes most closely for four of these functional domains, by using machine-learning techniques. This is the first study aiming to quantify which rodent model recapitulates the neuropathological features of SCZ most closely. The methodology and findings presented here support recent efforts to overcome translational hurdles of preclinical psychiatric research by associating behavioural endophenotypes with distinct biological processes.




Figure 1. Overview representing methodology and experimental steps used in this analysis.

Fig. 1

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2017.01.1563>

EV1234

The geometrical analysis of handwriting as a new tool to evaluate motor symptoms in psychosis

Y. Crespo Cobo^{1,*}, A. Ibañez Molina², S. Iglesias Parro², M.F. Soriano Peña³, J.I. Aznarte³

¹ FIBAO, Psychology, Jaén, Spain

² University of Jaén, Psychology, Jaén, Spain

³ Hospital San Agustín, Mental Health Unit, Linares, Spain

* Corresponding author.

Introduction There is growing evidence about the importance of motor symptoms in psychosis. Motor abnormalities have been observed in naive-drugs, first-episode patients. Clinical assessment of motor abnormalities normally relies upon subjective observer-based ratings. Kinematic analysis of handwriting has proved to be an objective measure of motor symptoms, but it has not been used in clinical settings.

Objectives In the present work, the geometrical analysis of handwriting patterns is proposed as a new tool to evaluate motor symptoms in psychosis.